natgillin/translations-raw huggingface dataset:
A population pharmacokinetic analysis evaluated avatrombopag plasma exposures in patients with mild to moderate hepatic impairment based on Model for End-Stage Liver Disease (MELD) scores and Child-Turcotte-Pugh scores.
S populacijsko farmakokinetično analizo so ocenili plazemsko izpostavljenost avatrombopagu pri bolnikih z blago do zmerno okvaro jeter na podlagi točk po prognostičnem modelu napredovale jetrne bolezni (MELD - Model for End-Stage Liver Disease) in točk po Child-Turcotte-Pughovi lestvici.
- you are allergic to avatrombopag or any of the other ingredients of this medicine (listed in section 6).
Kaj morate vedeti, preden boste vzeli zdravilo Doptelet Ne jemljite zdravila Doptelet: če ste alergični na avatrombopag ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Hypersensitivity to avatrombopag or to any of the excipients listed in section 6.1.
Preobčutljivost na avatrombopag ali katero koli pomožno snov, navedeno v poglavju 6.1. 4.4 Posebna opozorila in previdnostni ukrepi
Moderate CYP2C9 and strong CYP3A inducer
Zmerni zaviralec CYP2C9 in močan zaviralec CYP3A
Pharmacokinetics and pharmacodynamics of avatrombopag have not been investigated in patients with severe renal impairment (CrCL < 30 mL/min, Cockcroft-Gault) including patients requiring haemodialysis.
(CrCL < 30 ml/min, Cockcroft-Gault), vključno z bolniki, ki potrebujejo hemodializo, niso preučevali.
Due to limited information available, the safety and efficacy of avatrombopag in patients with severe hepatic impairment (Child-Pugh class C, MELD score > 24) have not been established (see section 4.4).
Varnost in učinkovitost avatrombopaga pri bolnikih s hudo okvaro jeter (razred C po Child-Pughovi lestvici, > 24 točk po lestvici MELD) zaradi pomanjkanja podatkov še nista bili dokazani (glejte poglavje 4.4).
Lactose monohydrate Microcrystalline cellulose (E460(i)) Crospovidone type B (E1202) Silica, colloidal anhydrous (E551) Magnesium stearate (E470b)
Mikrokristalna celuloza (E460(i)) Krospovidon tipa B (E1202) Brezvoden koloidni silicijev dioksid (E551) Magnezijev stearat (E470b)
Two doses should not be taken at one time to make up for a missed dose.
Bolnik ne sme vzeti dvojnega odmerka, da bi nadomestil izpuščenega.
Co-administered drug*
Sočasno uporabljeno zdravilo*
- The active substance is avatrombopag.
Učinkovina je avatrombopag.
Strong CYP3A inhibitor
Močan zaviralec CYP3A
Doptelet 20 mg film-coated tablets avatrombopag
Doptelet 20 mg filmsko obložene tablete avatrombopag
Doptelet 20 mg tablets avatrombopag
IME ZDRAVILA Doptelet 20 mg tablete avatrombopag
No dosage adjustment is necessary for patients with mild (Child-Pugh class A) to moderate (Child-Pugh class B) hepatic impairment.
Pri bolnikih z blago (razred A po Child-Pughovi lestvici) ali zmerno (razred B po Child-Pughovi lestvici) okvaro jeter prilagoditev odmerka ni potrebna.
In each study, patients were assigned to the low baseline platelet count cohort (˂ 40 x 109/L) or the high baseline platelet count cohort (≥ 40 to ˂ 50 x 109/L) based on their platelet count at baseline.
V posamezni študiji so bili bolniki na podlagi njihovega števila trombocitov ob izhodišču razvrščeni bodisi v kohorto bolnikov z majhnim številom trombocitov ob izhodišču (˂ 40 x 109/l) ali pa v kohorto bolnikov z velikim številom trombocitov ob izhodišču (≥ 40 do ˂ 50 x 109/l).
There is limited information on the use of avatrombopag in patients with severe (Child-Pugh class C, MELD score > 24) hepatic impairment.
Huda okvara jeter O uporabi avatrombopaga pri bolnikih s hudo okvaro jeter (razred C po Child-Pughovi lestvici,
Strong CYP3A4/5 or CYP2C9 inducers
Močni induktorji CYP3A4/5 ali CYP2C9
If you are not sure, talk to your doctor or pharmacist before taking Doptelet.
Če dojite, se posvetujte z zdravnikom ali farmacevtom, preden vzamete zdravilo Doptelet.
Low baseline platelet count cohort (< 40 x 109/L)
Kohorta bolnikov z majhnim številom trombocitov ob izhodišču (< 40 x 109/l)
P-gp and moderate CYP3A inhibitor
Zaviralec P-gp in zmerni zaviralec CYP3A Verapamil
CYP3A4/5 and CYP2C9 inhibitors
Zaviralci CYP3A4/5 in CYP2C9
Moderate CYP3A and CYP2C9 inhibitor
Zmerni zaviralec CYP3A in CYP2C9 Flukonazol
Contains lactose, see leaflet for further information.
Za več informacij glejte navodilo za uporabo.
Macrogol 3350 (E1521) Titanium dioxide (E171) Iron oxide yellow (E172)
Filmska obloga Polivinilalkohol (E1203) Smukec (E553b) Makrogol 3350 (E1521) Titanijev dioksid (E171) Rumeni železov oksid (E172)
However, there was a significant reduction (by approximately 50%) in the between- and within-subject variability of avatrombopag AUC and Cmax when administered with food (see sections 4.2 and 4.5).
Vendar pa so pri dajanju skupaj s hrano (glejte poglavji 4.2 in 4.5) ugotovili pomembno zmanjšanje (za približno 50%) interindividualne in intraindividualne variabilnosti za AUC in Cmax avatrombopaga.
Avatrombopag was present in milk of lactating rats after oral administration of radioactive labeled avatrombopag.
Po peroralnem dajanju radioaktivno označenega avatrombopaga so v mleku doječih podgan ugotovili prisotnost avatrombopaga.
Doptelet 20 mg film-coated tablets
IME ZDRAVILA Doptelet 20 mg filmsko obložene tablete
Hepatic impairment
Žilne bolezni
Retreatment
ZDRAVILA
In the high baseline platelet count cohort, the mean baseline platelet count for the avatrombopag-treated patients was 44.3 x 109/L and for placebo-treated patients was 44.9 x 109/L.
V kohorti bolnikov z velikim številom trombocitov ob izhodišču je povprečno število trombocitov ob izhodišču pri bolnikih, zdravljenih z avatrombopagom, znašalo 44,3 x 109/l, pri bolnikih, zdravljenih s placebom, pa 44,9 x 109/l.
Avatrombopag has not been studied in patients with severe renal impairment (see section 5.2); however, given the short duration of treatment, no dose adjustment is recommended.
Pri bolnikih s hudo okvaro ledvic avatrombopaga niso proučevali (glejte poglavje 5.2.
How to store Doptelet
Shranjevanje zdravila Doptelet
Based on in vitro studies, no other transporting proteins (OATP1B1, OATP1B3, OCT2, OAT1, and OAT3) are expected to play a significant role in the disposition of avatrombopag.
OATP1B3, OCT2, OAT1 oz. OAT3) imela pomembno vlogo pri porazdelitvi avatrombopaga.
In the high baseline platelet count cohort, the mean baseline platelet count for the avatrombopag-treated patients was 44.3 x 109/L and for placebo-treated patients was 44.5 x 109/L.
V kohorti bolnikov z velikim številom trombocitov ob izhodišču je povprečno število trombocitov ob izhodišču pri bolnikih, zdravljenih z avatrombopagom, znašalo 44,3 x 109/l, pri bolnikih, zdravljenih s placebom, pa 44,5 x 109/l.
Bone pain Myalgia
Ok vara jeter
Population pharmacokinetic analysis of avatrombopag plasma concentrations from clinical studies with healthy subjects and patients with thrombocytopenia due to chronic liver disease, that included 11% (84/787) of the study population ≥ 65 years of age, suggested that avatrombopag exposures are not affected by age (see section 4.2).
11% (84/787) študijske populacije preiskovancev, starih ≥ 65 let, je pokazala, da starost ne vpliva na izpostavljenost avatrombopagu (glejte poglavje 4.2).
Driving and using machines
OZNAČEVANJE IN NAVODILA ZA UPORABO
Package leaflet: Information for the patient Doptelet 20 mg film-coated tablets avatrombopag This medicine is subject to additional monitoring.
Navodilo za uporabo: Informacije za bolnika Doptelet 20 mg filmsko obložene tablete avatrombopag
Doptelet 20 mg
PODATKI V BRAILLOVI PISAVI Doptelet 20 mg
Avatrombopag 40 mg (n = 58) Proportion of subjects not requiring a platelet transfusion or rescue procedure for bleeding Responders 95% CIa P-valueb Proportion of subjects who achieved a platelet count ≥ 50 × 109/L on procedure day Responders 95% CIa P-valueb Change in platelet count from baseline to procedure day Mean (SD) x 109/L Median x 109/L P-valuec a Two-sided 95% confidence interval based on normal approximation.
Povprečna vrednost x 109/l P-vrednostc a Dvostranski 95-odstotni interval zaupanja na osnovi normalne aproksimacije.
Obtain a platelet count prior to the administration of Doptelet therapy and on the day of a procedure to ensure an adequate increase in platelet count, and no unexpectedly high increase in platelet count in the patient populations specified in sections 4.4 and 4.5.
Doptelet in na dan posega, določite število trombocitov, da zagotovite zadostno povečanje števila trombocitov in odsotnost nepričakovano velikega povečanja števila trombocitov.
No clinically important difference in avatrombopag exposures were observed between patients with Child-Turcotte-Pugh Scores (Range = 5 to 12) or MELD scores (Range = 4 to 23) and healthy subjects.
Med bolniki, ocenjenimi s točkami (razpon = 5 do 12) po Child-Turcotte-Pughovi lestvici, oz. bolniki,
In the low baseline platelet count cohort, the mean baseline platelet count for the avatrombopag-treated group was 32.7 x 109/L and for placebo-treated patients was 32.5 x 109/L.
zdravljenih z avatrombopagom, znašalo 32,7 x 109/l, pri bolnikih, zdravljenih s placebom, pa
Verapamil
Mialgija
Avatrombopag 60 mg (n = 70) Proportion of subjects not requiring a platelet transfusion or rescue procedure for bleeding Responders 95% CIa P-valueb Proportion of subjects who achieved a platelet count ≥ 50 × 109/L on procedure day Responders 95% CIa P-valueb Change in platelet count from baseline to procedure day Mean (SD) x 109/L Median x 109/L P-valuec
Sprememba števila trombocitov od izhodišča do dneva posega Povprečna vrednost (SD) x 109/l Povprečna vrednost x 109/l
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM Dova Pharmaceuticals Ireland Limited
In the low baseline platelet count cohort, the mean baseline platelet count for the avatrombopag-treated group was 31.1 x 109/L and for placebo-treated patients was 30.7 x 109/L.
zdravljenih z avatrombopagom, znašalo 31,1 x 109/l, pri bolnikih, zdravljenih s placebom, pa
Memantine Accord should be given once a day at the same time every day.
Zdravilo Memantine Accord se daje enkrat dnevno, vsak dan ob istem času.
It is used to treat patients with moderate to severe Alzheimer's disease, a type of dementia (a brain disorder) that gradually affects memory, intellectual ability and behaviour.
Uporablja se za zdravljenje bolnikov z zmerno do hudo Alzheimerjevo boleznijo, ki je vrsta demence (možganske bolezni), ki postopoma prizadene spomin, intelektualno sposobnost in vedenje.
To prevent side effects, the dose of Memantine Accord is gradually increased over the first three weeks of treatment: during the first week, the daily dose is 5 mg; in the second week, it is 10 mg; and during the third week, it is 15 mg. From week four onwards, the recommended maintenance dose is 20 mg once a day.
Da se preprečijo neželeni učinki, se odmerek zdravila Memantine Accord v prvih treh tednih zdravljenja postopoma povečuje: prvi teden je odmerek 5 mg; drugi teden 10 mg, tretji teden pa 15 mg. Od četrtega tedna naprej je priporočeni vzdrževalni odmerek 20 mg enkrat na dan.
Memantine Accord is available as tablets (5 mg, 10 mg, 15 mg and 20 mg) and can only be obtained with a prescription.
Zdravilo Memantine Accord je na voljo v obliki tablet (5 mg, 10 mg, 15 mg in 20 mg) in se izdaja le na recept.
The full EPAR for Memantine Accord can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Memantine Accord je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
This means that Memantine Accord is similar to a ‘reference medicine' already authorised in the European Union (EU) called Axura.
To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Axura.
Memantine works by blocking types of receptors called N-methyl-D-aspartate (NMDA) receptors, to which the neurotransmitter glutamate normally attaches.
Memantin deluje tako, da zavira vrsto receptorjev, imenovanih receptorji za N-metil-D-aspartat (NMDA), na katere se navadno veže živčni prenašalec glutamat.
This is a summary of the European public assessment report (EPAR) for Memantine Accord.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Memantine Accord.
The company provided data on the medicine's solubility, composition and absorption in the body.
Družba je predložila podatke o topnosti in sestavi zdravila ter o njegovi absorpciji v telesu.
Treatment should only be started if a caregiver is available who will regularly monitor the use of Memantine Accord by the patient.
Zdravljenje se sme uvesti samo, če je na voljo negovalec, ki bo redno spremljal bolnikovo uporabo zdravila Memantine Accord.
The Committee recommended that Memantine Accord be approved for use in the EU.
Priporočil je, da se zdravilo Memantine Accord odobri za uporabo v EU.
Because Memantine Accord is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Ker je zdravilo Memantine Accord generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
By blocking NMDA receptors, memantine improves the transmission of signals in the brain and reduces the symptoms of Alzheimer's disease.
Memantin z zaviranjem receptorjev NMDA izboljša prenos signalov v možganih in zmanjša simptome Alzheimerjeve bolezni.
The European Commission granted a marketing authorisation valid throughout the European Union for Memantine Accord on 04 December 2013.
Evropska komisija je dovoljenje za promet z zdravilom Memantine Accord, veljavno po vsej Evropski uniji, izdala 04. decembra 2013.
What measures are being taken to ensure the safe and effective use of Memantine Accord?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Memantine Accord?
A risk management plan has been developed to ensure that Memantine Accord is used as safely as possible.
Za zagotovitev čim varnejše uporabe zdravila Memantine Accord je bil pripravljen načrt obvladovanja tveganj.
What are the benefits and risks of Memantine Accord?
Kakšne so koristi in tveganja, povezani z zdravilom Memantine Accord?
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Memantine Accord, including the appropriate precautions to be followed by healthcare professionals and patients.
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila Memantine Accord in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
The tolerance and dose should be assessed within three months after starting treatment, and from then on the benefits of continuing treatment with Memantine Accord should be re-assessed on a regular basis.
Accord je treba oceniti v 3 mesecih od začetka zdravljenja, nato pa je treba redno ocenjevati koristi nadaljnjega zdravljenja s tem zdravilom.
What is Memantine Accord and what is it used for?
Kaj je zdravilo Memantine Accord in za kaj se uporablja?
For practical information about using Memantine Accord, patients should read the package leaflet or contact their doctor or pharmacist.
Za praktične informacije o uporabi zdravila Memantine Accord naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Memantine Accord has been shown to have comparable quality and is considered bioequivalent to Axura.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Memantine Accord primerljivo raven kakovosti kot referenčno zdravilo Axura ter da mu je biološko enakovredno.
For more information about treatment with Memantine Accord, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju s tem zdravilom preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Other information about Memantine Accord
Druge informacije o zdravilu Memantine Accord
Memantine Accord is a ‘generic medicine'.
Zdravilo Memantine Accord je „generično zdravilo“.
No additional studies in patients were required as Memantine Accord was shown to have comparable quality and is considered to be bioequivalent to the reference medicine, Axura.
Dodatne študije pri bolnikih niso bile potrebne, ker je bilo dokazano, da ima zdravilo Memantine Accord primerljivo raven kakovosti kot referenčno zdravilo Axura ter da mu je biološko enakovredno.
Memantine Accord is a medicine that contains the active substance memantine.
Memantine Accord je zdravilo, ki vsebuje zdravilno učinkovino memantin.
Therefore, the CHMP's view was that, as for Axura, the benefit outweighs the identified risk.
Zato je menil, da njegove koristi tako kot pri zdravilu Axura odtehtajo znana tveganja.
The active substance in Memantine Accord, memantine, is an antidementia medicine.
Zdravilna učinkovina v zdravilu Memantine Accord, memantin, je zdravilo za zdravljenje demence.
It is not intended to provide practical advice on how to use Memantine Accord.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
Why is Memantine Accord approved?
Zakaj je bilo zdravilo Memantine Accord odobreno?
How has Memantine Accord been studied?
Kako je bilo zdravilo Memantine Accord raziskano?
How is Memantine Accord used?
Kako se zdravilo Memantine Accord uporablja?
How does Memantine Accord work?
Kako zdravilo Memantine Accord deluje?
Although this difference is not large, it may benefit some patients.
Čeprav ta razlika ni velika, lahko nekaterim bolnikom koristi.
There is a risk of severe allergic reactions, and although it is not known exactly how often these reactions occur, they appear to be rare.
Obstaja tveganje za hude alergijske reakcije in čeprav ni znano, kako pogosto se te reakcije pojavljajo, se zdijo redke.
It is given once only, within 48 hours after symptoms start.
Zdravilo se da samo enkrat, v 48 urah po začetku simptomov.
Further information on Alpivab can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Nadaljnje informacije za zdravilo Alpivab so na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The European Medicines Agency decided that Alpivab's benefits are greater than its risks and it can be authorised for use in the EU.
Evropska agencija za zdravila je zaključila, da so koristi zdravila Alpivab večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
The dose depends on age and body weight and should be reduced in adults and adolescents over 13 years of age with reduced kidney function.
Odmerek je odvisen od starosti in telesne mase ter ga je treba zmanjšati pri odraslih in mladostnikih, starejših od 13 let, z zmanjšanim delovanjem ledvic.
What measures are being taken to ensure the safe and effective use of Alpivab?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Alpivab?
Alpivab is given as an infusion lasting 15 to 30 minutes.
Zdravilo Alpivab se daje v obliki infuzije, ki traja od 15 do 30 minut.
It is used to treat uncomplicated influenza (flu) in adults and children over 2 years.
Uporablja se zdravljenje nezapletene influence (gripe) pri odraslih in otrocih, starejših od dveh let.
As for all medicines, data on the use of Alpivab are continuously monitored.
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Alpivab stalno spremljajo.
Other information about Alpivab
Druge informacije o zdravilu Alpivab
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Alpivab have been included in the summary of product characteristics and the package leaflet.
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Alpivab upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
Side effects reported with Alpivab are carefully evaluated and any necessary action taken to protect patients.
Neželeni učinki, o katerih so poročali pri zdravilu Alpivab, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
What benefits of Alpivab have been shown in studies?
Kakšne koristi zdravila Alpivab so se pokazale v študijah?
What is Alpivab and what is it used for?
Kaj je zdravilo Alpivab in za kaj se uporablja?
Why is Alpivab authorised in the EU?
Zakaj je bilo zdravilo Alpivab odobreno v EU?
For more information about using Alpivab, see the package leaflet or contact your doctor or pharmacist.
Za več informacij glede uporabe zdravila Alpivab glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
An overview of Alpivab and why it is authorised in the EU
Pregled zdravila Alpivab in zakaj je odobreno v EU
What are the risks associated with Alpivab?
Kakšna tveganja so povezana z zdravilom Alpivab?
Alpivab reduces the length of time flu symptoms last by one day on average.
Zdravilo Alpivab skrajša trajanje simptomov gripe povprečno za en dan.
Alpivab is an antiviral medicine that contains the active substance peramivir.
Alpivab je protivirusno zdravilo, ki vsebuje učinkovino peramivir.
Uncomplicated means that the flu has typical features (such as fever, aches, cough, sore throat and runny nose) and is not made worse by other conditions.
Nezapletena gripa pomeni, da ima ta tipične značilnosti (npr. vročino, bolečine, kašelj, boleče grlo in izcedek iz nosu) in ne poteka težje zaradi drugih bolezni.
Peramivir works on neuraminidases of both influenza-A (the most common type) and influenza-B viruses.
Peramivir deluje na nevraminidaze virusov influence A (najpogostejša vrsta) in influence B.
Serious side effects with Alpivab are anaphylaxis (a severe allergic reaction) and skin reactions, including erythema multiforme (an allergic skin reaction) and Stevens-Johnson Syndrome (life-threatening reaction with flu-like symptoms and painful rash affecting the skin, mouth, eyes and genitals).
Resni neželeni učinki zdravila Alpivab so anafilaksija (huda alergijska reakcija) in kožne reakcije, vključno z multiformnim eritemom (alergijsko kožno reakcijo) in Stevens-Johnsonovim sindromom (življenjsko nevarno reakcijo z gripi podobnimi simptomi in bolečim izpuščajem, ki se pojavi na koži, v ustih, na očeh in na spolovilu).
Alpivab was compared with placebo (a dummy treatment) in one main study of 296 adults with influenza (mostly influenza A) treated within 48 hours of symptoms appearing.
Zdravilo Alpivab so primerjali s placebom (zdravilom brez učinkovine) v eni glavni študiji pri 296 odraslih bolnikih z influenco (večinoma influenco A), zdravljenih v 48 urah po pojavu simptomov.
The active substance in Alpivab, peramivir, prevents the flu virus from spreading further by blocking the activity of enzymes (proteins) on the surface of the virus called neuraminidases.
Učinkovina v zdravilu Alpivab, peramivir, preprečuje nadaljnje širjenje virusa tako, da zavira dejavnost encimov (beljakovin) na površini virusa, imenovanih nevraminidaze.
The main measure of effectiveness was the length of time before symptoms (cough, sore throat, headache, blocked nose, feverishness or chills, aches or pains of the muscle or joints and tiredness) got better.
Glavno merilo učinkovitosti je bilo trajanje obdobja pred izboljšanjem simptomov (kašlja, bolečega grla, glavobola, zamašenega nosu, vročičnosti ali mrzlice, bolečin v mišicah ali sklepih in utrujenosti).
The most common side effects with Alpivab (which may affect up to around 3 in 100 people) are a decrease in the levels of neutrophils (a type of white blood cell) and nausea (feeling sick).
Najpogostejša neželena učinka zdravila Alpivab (ki se lahko pojavita pri več kot 3 od 100 bolnikov) sta zmanjšanje števila nevtrofilcev (vrste belih krvnih celic) in navzea (siljenje na bruhanje).